Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 384.50% | 118.40% | 104.75% | 103.65% | 93.15% |
| Total Depreciation and Amortization | -56.33% | -55.01% | -46.40% | -41.12% | -16.07% |
| Total Amortization of Deferred Charges | -100.00% | -75.44% | -56.25% | -30.00% | 0.00% |
| Total Other Non-Cash Items | -57.07% | -93.36% | -90.73% | -90.29% | -81.52% |
| Change in Net Operating Assets | -94.11% | 67.38% | 62.79% | 86.37% | -7.69% |
| Cash from Operations | 93.93% | 281.73% | 148.97% | 149.26% | 127.48% |
| Capital Expenditure | -69.66% | -25.97% | -17.66% | -45.96% | -81.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -92.20% | -94.13% | -94.13% | -107.00% |
| Cash from Investing | 14.85% | -100.32% | -100.81% | -101.40% | -114.62% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -64.00% | -310.00% | -833.33% | -- | 68.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -98.11% |
| Repurchase of Common Stock | 70.37% | 70.37% | 70.37% | 70.37% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -154.49% | -526.25% | -424.92% | -267.73% | -159.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.58% | -203.24% | -211.54% | -187.85% | -144.36% |
